Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases

Abstract Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Velayudhan Mohan Kumar, Seithikurippu R. Pandi-Perumal, Ilya Trakht, Sadras Panchatcharam Thyagarajan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2ac300acef9c4ca2881395e8e3dad3f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2ac300acef9c4ca2881395e8e3dad3f0
record_format	dspace
spelling	oai:doaj.org-article:2ac300acef9c4ca2881395e8e3dad3f02021-12-02T18:27:46ZStrategy for COVID-19 vaccination in India: the country with the second highest population and number of cases10.1038/s41541-021-00327-22059-0105https://doaj.org/article/2ac300acef9c4ca2881395e8e3dad3f02021-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00327-2https://doaj.org/toc/2059-0105Abstract Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical trials in India, four were developed in the country. India’s drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home-grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country’s future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic are sufficient for the initial vaccination of 30 million healthcare workers. The Indian government has taken urgent measures to expand the country’s vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration.Velayudhan Mohan KumarSeithikurippu R. Pandi-PerumalIlya TrakhtSadras Panchatcharam ThyagarajanNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Velayudhan Mohan Kumar Seithikurippu R. Pandi-Perumal Ilya Trakht Sadras Panchatcharam Thyagarajan Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases
description	Abstract Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical trials in India, four were developed in the country. India’s drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home-grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country’s future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic are sufficient for the initial vaccination of 30 million healthcare workers. The Indian government has taken urgent measures to expand the country’s vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration.
format	article
author	Velayudhan Mohan Kumar Seithikurippu R. Pandi-Perumal Ilya Trakht Sadras Panchatcharam Thyagarajan
author_facet	Velayudhan Mohan Kumar Seithikurippu R. Pandi-Perumal Ilya Trakht Sadras Panchatcharam Thyagarajan
author_sort	Velayudhan Mohan Kumar
title	Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases
title_short	Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases
title_full	Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases
title_fullStr	Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases
title_full_unstemmed	Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases
title_sort	strategy for covid-19 vaccination in india: the country with the second highest population and number of cases
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2ac300acef9c4ca2881395e8e3dad3f0
work_keys_str_mv	AT velayudhanmohankumar strategyforcovid19vaccinationinindiathecountrywiththesecondhighestpopulationandnumberofcases AT seithikurippurpandiperumal strategyforcovid19vaccinationinindiathecountrywiththesecondhighestpopulationandnumberofcases AT ilyatrakht strategyforcovid19vaccinationinindiathecountrywiththesecondhighestpopulationandnumberofcases AT sadraspanchatcharamthyagarajan strategyforcovid19vaccinationinindiathecountrywiththesecondhighestpopulationandnumberofcases
_version_	1718378030433304576

Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases

Ejemplares similares